Soekojo CY - Search Results

1

Soekojo CY, Ooi M, de Mel S, Chng WJ. Soekojo CY, et al. Cells. 2020 Mar 3;9(3):601. doi: 10.3390/cells9030601. Cells. 2020. PMID: 32138182 Free PMC article. Review.

2

Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma.

Jia Y, Zhou J, Tan TK, Chung TH, Wong RWJ, Chooi JY, Lim JSL, Sanda T, Ooi M, De Mel S, Soekojo C, Chen Y, Zhang E, Cai Z, Shen P, Ruan J, Chng WJ. Jia Y, et al. Blood Cancer J. 2021 Feb 12;11(2):32. doi: 10.1038/s41408-021-00421-7. Blood Cancer J. 2021. PMID: 33579893 Free PMC article.

3

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis.

Teoh PJ, An O, Chung TH, Chooi JY, Toh SHM, Fan S, Wang W, Koh BTH, Fullwood MJ, Ooi MG, de Mel S, Soekojo CY, Chen L, Ng SB, Yang H, Chng WJ. Teoh PJ, et al. Among authors: soekojo cy. Blood. 2018 Sep 20;132(12):1304-1317. doi: 10.1182/blood-2018-02-832576. Epub 2018 Jul 30. Blood. 2018. PMID: 30061158 Free article.

4

The evolution of immune dysfunction in multiple myeloma.

Soekojo CY, Chng WJ. Soekojo CY, et al. Eur J Haematol. 2022 Nov;109(5):415-424. doi: 10.1111/ejh.13839. Epub 2022 Sep 19. Eur J Haematol. 2022. PMID: 35880386 Review.

5

Treatment horizon in multiple myeloma.

Soekojo CY, Chng WJ. Soekojo CY, et al. Eur J Haematol. 2022 Nov;109(5):425-440. doi: 10.1111/ejh.13840. Epub 2022 Sep 18. Eur J Haematol. 2022. PMID: 35880395 Review.

6

Potential Clinical Application of Genomics in Multiple Myeloma.

Soekojo CY, de Mel S, Ooi M, Yan B, Chng WJ. Soekojo CY, et al. Int J Mol Sci. 2018 Jun 10;19(6):1721. doi: 10.3390/ijms19061721. Int J Mol Sci. 2018. PMID: 29890777 Free PMC article. Review.

7

Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis.

Soekojo CY, Wang GM, Chen Y, Casan J, Wolyncewicz G, Lin A, Poon LM, de Mel S, Koh LP, Tan LK, Ooi MG, Nagarajan C, Liu Y, Lai YY, Huang XJ, Spencer A, Gopalakrishnan SK, Lu J, Chng WJ. Soekojo CY, et al. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e470-e477. doi: 10.1016/j.clml.2019.04.011. Epub 2019 Apr 28. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31171473

8

Bacterial Infection Among Patients With Multiple Myeloma Treated With Bortezomib-based Induction Therapy: Real-World Experience in an Asian Cancer Center.

Soekojo CY, Low JZ, Oh J, Ooi M, De Mel S, Chng WJ. Soekojo CY, et al. Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):e165-e170. doi: 10.1016/j.clml.2019.12.024. Epub 2020 Jan 9. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32019731

9

Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis.

Chong LL, Soon YY, Soekojo CY, Ooi M, Chng WJ, de Mel S. Chong LL, et al. Among authors: soekojo cy. Crit Rev Oncol Hematol. 2021 Mar;159:103211. doi: 10.1016/j.critrevonc.2020.103211. Epub 2020 Dec 30. Crit Rev Oncol Hematol. 2021. PMID: 33387628 Review.

10

Genomic characterization of functional high-risk multiple myeloma patients.

Soekojo CY, Chung TH, Furqan MS, Chng WJ. Soekojo CY, et al. Blood Cancer J. 2022 Jan 31;12(1):24. doi: 10.1038/s41408-021-00576-3. Blood Cancer J. 2022. PMID: 35102139 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters